Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.71 |
| ▸ | PRNP | P04156 | 1/20 | 0.71 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.62 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.59 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.56 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | IKBKB | O14920 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | EDNRA | P25101 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29939764 | 1.00 | RXFP1 (0.71) | RXFP1PRNPMCL1HSD11B1GPR35 | |
| SCHEMBL16598796 | 0.86 | RXFP1 (0.73) | RXFP1PRNPMCL1HSD11B1LIMK1 | |
| SCHEMBL6621845 | 0.85 | RXFP1 (0.62) | RXFP1PRNPMCL1HSD11B1GPR35 | |
| SCHEMBL2610250 | 0.85 | RXFP1 (0.61) | RXFP1PRNPMCL1HSD11B1LIMK1 | |
| SCHEMBL29483598 | 0.83 | LIMK1 (0.68) | RXFP1PRNPMCL1HSD11B1LIMK1 | |
| SCHEMBL2610245 | 0.83 | RXFP1 (0.59) | RXFP1PRNPMCL1HSD11B1LIMK1 | |
| SCHEMBL2702750 | 0.83 | LIMK1 (0.68) | RXFP1PRNPMCL1HSD11B1LIMK1 | |
| Potassium Ion SCHEMBL15876132 | 0.81 | RXFP1 (0.62) | RXFP1PRNPMCL1HSD11B1LIMK1 | |
| SCHEMBL9591868 | 0.80 | RXFP1 (0.56) | RXFP1PRNPMCL1HSD11B1LIMK1 | |
| SCHEMBL4834908 | 0.80 | HSD11B1 (0.62) | RXFP1PRNPMCL1HSD11B1LIMK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106748604-B | Method for synthesizing mono-iodo aromatic hydrocarbon or di-iodo aromatic hydrocarbon based on decarboxylation of aromatic carboxylic acid | 湘潭大学 | 2020-06-05 | — | — | CN | claimed |
| CN-107188846-B | A kind of synthetic method of arylseleno heterocyclic compound | 温州医科大学 | 2019-08-20 | — | — | CN | claimed |
| CN-107188846-A | A kind of synthetic method of arylseleno heterocyclic compound | 温州医科大学 | 2017-09-22 | — | — | CN | claimed |
| CN-106748604-A | A kind of method for synthesizing single iodo aromatic hydrocarbon or two iodo aromatic hydrocarbons based on aromatic carboxylic acid's decarboxylic reaction | 湘潭大学 | 2017-05-31 | — | — | CN | claimed |
| US-20250346575-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-11-13 | — | — | US | disclosed |
| US-20250092009-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2025-03-20 | — | — | US | disclosed |
| EP-4431505-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | Korea Research Institute of Chemical Technology (KR) | 2024-09-18 | — | — | EP | disclosed |
| CN-115215823-B | FXR modulator, preparation method, pharmaceutical composition and application thereof | 北京百思致道管理顾问中心(有限合伙) | 2024-07-26 | — | — | CN | disclosed |
| US-20240239775-A1 | FXR REGULATOR, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | BEIJING BEST PATHWAY MANAGEMENT CONSULTING CENTER (LIMITED PARTNERSHIP) (CN) | 2024-07-18 | — | — | US | disclosed |
| CN-118234721-A | Isoindolinone derivative with glutarimide mother nucleus and application thereof | 韩国化学研究院 | 2024-06-21 | — | — | CN | disclosed |
| EP-4324825-A1 | FXR REGULATOR, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | Beijing Best Pathway Management Consulting Center (Limited Partnership) (CN) | 2024-02-21 | — | — | EP | disclosed |
| EP-3793988-B1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2023-11-15 | — | — | EP | disclosed |
| EP-1622610-A1 | 1-(2H-PYRAZOL-3-YL)-3- 4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL -UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | Aventis Pharmaceuticals Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20060020135-A1 | Long chain aliphatic alcohol derivatives and methods of making and using same | SINO PHARMACEUTICALS CORPORATION (CA) | 2006-01-26 | — | — | US | disclosed |
| WO-2005054176-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| WO-2004100946-A1 | 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| EP-1064276-B1 | PROCESS FOR SYNTHESIZING SUBSTITUTED 2-BENZO b] THIOPHENE CARBOXYLIC ACIDS AND SALTS THEREOF | UNIROYAL CHEM CO INC (US) | 2003-02-26 | — | — | EP | disclosed |
| WO-2001007431-A2 | BENZOTHIOPHENE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-02-01 | — | — | WO | disclosed |
| US-5965749-A | Process for synthesizing substituted 2-benzo [b]thiophenecarboxylic acids and salts thereof | UNIROYAL CHEMICAL COMPANY, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| WO-1994027985-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED 3-HALOMETHYL-BENZOTHIOPHENES, BENZOFURANS AND -INDOLES AND INTERMEDIATES THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239775-A1 | FXR REGULATOR, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | SLC10A1, NR1H4, FXR1 | RXFP1 327/4885PRNP 4722/4885MCL1 4555/4885 |
| US-20060020135-A1 | Long chain aliphatic alcohol derivatives and methods of making and using same | ADH1C, ADH5, NAPRT | RXFP1 4586/4885PRNP 3353/4885MCL1 4008/4885 |
| US-20250346575-A1 | ISOINDOLINONE DERIVATIVE HAVING GLUTARIMIDE MOTHER NUCLEUS, AND USE THEREOF | CRBN, IDH1, IDH2 | RXFP1 4212/4885PRNP 2189/4885MCL1 121/4885 |
| US-20250092009-A1 | SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING | STING1, CGAS, IRF3 | RXFP1 460/4885PRNP 4624/4885MCL1 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.